Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc.’s chief financial officer Mark S. Livingston reported a mix of equity grants and related tax withholdings. He received a grant of 45,454 shares of common stock as restricted stock units and a separate stock option for 66,289 shares, both as annual merit awards under the 2019 Equity Incentive Plan. In connection with RSU vesting, the company withheld 4,579 shares on one date and 181 shares on another date at prices around $17.60–$17.69 per share to cover tax obligations, leaving him with 87,677 common shares directly owned after the larger withholding transaction.
Progyny, Inc. CEO Peter Anevski reported equity compensation and related tax withholding transactions. On March 2, 2026, he was granted 159,091 shares of common stock as restricted stock units and 232,011 stock options, both as annual merit grants under Progyny’s 2019 Equity Incentive Plan.
These awards vest over three years, with 33% vesting after one year and the remainder vesting quarterly, subject to continued service. On March 3, 2026, 17,611 common shares were withheld to cover taxes upon RSU vesting, leaving 816,833 common shares held directly. An additional 1 share is held indirectly through PECO ANEVSKI 2020 SD LLC.
PGNY Form 144 notice lists proposed dispositions of common stock by Allison C. Swartz and a 599-share restricted stock vesting to Fidelity Brokerage Services LLC. The excerpt shows three sales by Allison C. Swartz: 12/04/2025 ($13,032.70, 530 shares), 03/02/2026 ($37,976.73, 2,199 shares) and 03/03/2026 ($81,029.55, 4,657 shares). It also lists 599 shares from a restricted stock vesting on 03/04/2026 associated with Fidelity Brokerage Services LLC and labeled Compensation.
Allison C. Swartz reported proposed and recent dispositions of PGNY common stock. The filing lists 4,657 shares to be sold in connection with restricted stock vesting on 03/03/2026. It also shows prior sales of 530 shares on 12/04/2025 (for $13,032.70) and 2,199 shares on 03/02/2026 (for $37,976.73).
Brokerage details name Fidelity Brokerage Services LLC as the broker of record and the securities are listed on NASDAQ.
Allison C. Swartz submitted a Form 144 notice reporting proposed transactions in common stock tied to restricted stock vesting as compensation. The filing lists 2,199 shares in the securities table and records a prior sale of 530 shares on 12/04/2025.
Progyny, Inc. files its annual report describing a fast‑growing women’s health and family building benefits platform. The company serves more than 590 self‑insured employers across over 40 industries, covering about 7.2 million employees and dependents through fertility, pharmacy, pregnancy, menopause and family support solutions.
Progyny highlights its proprietary Smart Cycle plan design, integrated Progyny Rx pharmacy benefit, selective Center of Excellence fertility network and concierge care advocates, which it says drive higher live birth rates and fewer multiple births than national averages. The filing also outlines extensive regulatory, competitive, macroeconomic, data privacy and technology (including AI) risks that could affect future growth and profitability.
Progyny, Inc. reported record 2025 results and raised its outlook for 2026. Full-year 2025 revenue reached $1,288.7 million, up 10% from 2024, or 20% excluding a large former client under a transition agreement. Gross profit rose 20% to $304.5 million, lifting gross margin to 23.6%.
Net income for 2025 was $58.5 million, or $0.65 per diluted share, with Adjusted EBITDA of $222.1 million and a 17.2% Adjusted EBITDA margin. Operating cash flow hit a record $210.2 million. As of December 31, 2025, Progyny had $310.1 million in cash and marketable securities, $349.4 million of working capital, and no debt.
In the fourth quarter, revenue was $318.4 million, up 6.7% year over year, or 21% excluding the former client, while gross margin expanded to 24.1%. The company repurchased 3.3 million shares for $83.6 million in the quarter and about 6.5 million shares to date, spending roughly $160 million under its $200 million authorization.
For 2026, Progyny projects revenue of $1.355 billion to $1.405 billion, net income of $95.4 million to $106.1 million (or $1.10 to $1.22 per diluted share), Adjusted EBITDA of $224.0 million to $239.0 million, and continued revenue growth excluding the transitioned client.
Progyny, Inc. furnished an update to its previously issued financial guidance for the three months and full year ending December 31, 2025. The company did this by issuing a press release dated January 12, 2026, which is attached as Exhibit 99.1 to this Form 8-K and incorporated by reference into the disclosure under Item 2.02. The information in this item and the exhibit is being furnished rather than filed under securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other regulatory documents.
Progyny, Inc. announced that the employment of its President, Michael Sturmer, will end effective December 31, 2025, with severance provided under his existing 2021 employment agreement. The company is not appointing a new President, noting that it has strengthened its executive team with recent hires in commercial, technology, operations and product leadership roles.
To support continuity on key projects and strategic initiatives, Sturmer will remain as a non-employee consultant through December 31, 2026, under a new consulting agreement. He will receive an annual advisory fee of $250,000, and if he continues to serve through June 30, 2026, his outstanding and vested stock options will have their exercisability extended proportionally to the period of consulting services. The full consulting agreement will be filed as an exhibit to Progyny’s Annual Report on Form 10-K for the year ending December 31, 2025.
Progyny, Inc. reported an insider stock transaction by its chief financial officer, Mark S. Livingston. On December 11, 2025, he sold 459 shares of Progyny common stock at $25.5 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. Following this transaction, he directly owns 46,983 shares of Progyny common stock.